Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study

Circulation

Volumn 100, Issue 1, 1999, Pages 61-66

  Valantine, Hannah A ^a   Gao, Shao Zhou ^a   Menon, Santosh G ^b   Renlund, Dale G ^b   Hunt, Sharon A ^a   Oyer, Philip ^a   Stinson, Edward B ^a   Brown Jr , Byron W ^a   Merigan, Thomas C ^a   Schroeder, John S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Atherosclerosis; Cytomegalovirus; Ganciclovir; Transplantation

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; GANCICLOVIR; OKT 3; PLACEBO; PREDNISONE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0033529381     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.1.61     Document Type: Article

References (20)

1. Keogh AM, Valantine HA, Hunt SA, Schroeder JS, McIntosh N, Oyer PE, Stinson EB. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11:892-901.
2. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Valantine HA, Wiederhold V, Stinson EB. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation. 1989;80(suppl III):III-100-III-105.
3. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB. A preliminary study of diltiazem in prevention of coronary artery disease in heart transplant recipients. N Engl J Med. 1993;328:164-170.
4. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasak PI, Sabad A, Cogert GA, Tosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
5. Speir E, Modali R, Huang E, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391-394.
6. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561-3566.
7. Loebe M, Schüler S, Zais O, Warnecke H, Fleck E, Hetzer R. Role of cytomegalovirus in the development of coronary artery disease. J Heart Transplant. 1990;9:707-711.
8. McDonald K, Rector TS, Braunlin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359-362.
9. Koskinen PK, Krogerus LA, Nieminen MS, Mattila SP, Häyry PJ, Lautenschlager IT. Quantitation of cytomegalovirus infection associated with histologic findings on endomyocardial biopsies of heart allografts. J Heart Lung Transplant. 1993;12:343-354.
10. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, Richenbacher WE, Millar RC, DuMond C, DeAmond B, Sullivan V, Cheney T, Buhles W, Stinson EB. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182-1186.
11. Wagner JA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC, Stinson EB. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation. 1995;60:1473-1477.
12. Valantine HA. Long-term management and results in heart transplant recipients. Cardiol Clin. 1990;8:141-148.
13. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 1988;12:334-340.
14. Uretsky BF, Kormos RL, Zerbe TR, Lee A, Tokarcyzk TR, Murali S, Reddy PS, Denys BG, Griffith BD, Hardesty RL, Armitage JM, Arena VC. Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. J Heart Lung Transplant. 1992;11: S45-S51.
15. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
16. Lemstrom KB, Bruning JH, Bruggeman CA, Koskinen PK, Aho PT, Yilmaz S, Lautenschlager IT, Häyry PJ. Cytomegalovirus infection enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation. 1994;90:1969-1978.
17. Lemstrom KB, Koskinin P, Krogerus L, Daemon M, Bruggeman C, Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimai thickening in rat cardiac allografts after cytomegalovirus infection. Circulation. 1995;92:2594-2602.
18. Parmley WW. Calcium channel blockers and atherogenesis. Am J Med. 1987;82(suppl 3B):3-8.
19. Thyberg J, Hedin U, Sjölund M, Palmberg L, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 1990;10:966-990.
20. Craigen JL, Grundy JE. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation. 1996; 62:1102-1108.